Acadia Pharmaceuticals announced full positive results from the Phase III HARMONY study evaluating Nuplazid (pimavanserin) for the treatment of dementia-related psychosis.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2019-12-05 12:06:502019-12-05 12:06:50Nuplazid Excels in Dementia-Related Psychosis Study
